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CASE REPORT
The patient is a 59-year-old woman who had cosmetic 
augmentation with Allergan 468 textured saline implants 
at age 41. In subsequent years, she underwent routine 
screening mammography according to recommended 
guidelines. Eighteen years after implant augmentation, 
she developed swelling of the left breast. Ultrasonography 
identified a periprosthetic fluid collection; aspiration of 
the seroma produced murky, yellow fluid. Cytologic anal-
ysis showed an atypical lymphocyte proliferation positive 
for CD3, CD30, and CD4, and negative for anaplastic 
lymphoma kinase (ALK), CD2, and CD5 by immunohis-
tochemistry. Whole body positron emission tomography 
with computed tomography (PET-CT) showed a nonavid 
seroma surrounding a deflated left breast implant, but 
no masses or other suspicious findings (Fig. 1A). Her 
previous screening mammogram 6 months earlier had 
been negative. She underwent implant removal with cap-
sulectomy which showed clusters of atypical pleomorphic 
cells with prominent nucleoli and horseshoe-shaped nu-
clei (hallmark cells) below the surface of the capsule with 
focal early invasion (Fig. 1B). The atypical cells showed 
positive immunohistochemical staining of CD30 (see fig-
ure, Supplemental Digital Content 1, which displays the 
BIA-ALCL was positive for CD30 by immunohistochem-
istry, http://links.lww.com/PRSGO/B33), CD3 (subset 
weak), CD4, T-cell intracytoplasmic antigen (TIA-1, sub-
set), and epithelial membrane antigen (EMA), and were 
negative for CD2, CD5, CD7, CD8, ALK, CD15, B-cell 
markers, and Epstein-Barr virus (EBV)-encoded RNA in 
situ hybridization, consistent with ALK-negative breast 
implant–associated anaplastic large cell lymphoma (BIA-
ALCL). The clinicopathologic stage was pT2.1
Six months later she underwent screening mammog-
raphy prior to the planned implant replacement and was 
found to have a spiculated mass in the upper outer left 
breast (Fig. 2A); this was not seen on the prior mammo-
gram 12 months earlier. Core needle biopsy showed inva-
sive ductal carcinoma (IDC), which was estrogen receptor 
positive, progesterone receptor positive, and HER2 nega-
tive. Diagnosed within 6 months of one another, the pa-
tient’s 2 tumors may be considered synchronous.2 With a 
family history of leukemia and cancer of the colon, lung, 
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and esophagus, the patient underwent germline testing 
with a panel of 85 breast cancer-associated genes (Invitae, 
San Francisco, Calif.). No pathogenic or likely pathogenic 
germline aberrations were detected. She then underwent 
left partial mastectomy, sentinel lymph node biopsy, and 
bilateral oncoplastic mammoplasty. Pathology showed 
a 1.2-cm grade 2 IDC (Fig. 2B) with negative margins, 1 
intramammary lymph node with micrometastatic car-
cinoma, and 2 negative sentinel nodes. The pathologic 
stage was pT1cN1mi(sn). Oncotype Dx testing of the IDC 
showed a low-risk recurrence score of 18. She was treated 
with hypofractionated whole breast radiotherapy with tan-
gents to the axilla, and an aromatase inhibitor.
After obtaining informed consent, we used capture-
based next-generation sequencing to more comprehen-
sively characterize both the BIA-ALCL and the IDC. This 
assay (UCSF500 panel) targets the coding regions of 479 
cancer-related genes, select introns from 41 genes, and 
the TERT promoter (see table, Supplemental Digital Con-
tent 2, which displays 479 cancer-related genes on the 
UCSF500 panel, http://links.lww.com/PRSGO/B34).
Sequencing libraries were prepared from genomic 
DNA of tumor and matched normal formalin-fixed, par-
affin-embedded tissue extracted from unstained sections. 
Target enrichment was performed by hybrid capture us-
ing a custom oligonucleotide library. Sequencing was per-
formed on a HiSeq 2500 (Illumina, San Diego, Calif.). In 
the BIA-ALCL, a pathogenic missense mutation in STAT3 
(p.S614R) was identified (Fig. 3A and B). Confirmatory 
immunohistochemistry for phospho-STAT3 (Tyr705) 
highlighted the tumor cells (Fig. 3C). Copy number analy-
sis showed chromosomal gains in 12p and 21q. Analysis of 
the IDC showed a likely pathogenic and activating in-frame 
deletion in PIK3CA (p.G106_R108del) (Fig. 4A and B). 
Numerous partial chromosomal gains and losses were 
identified; no focal amplifications or deep deletions were 
Fig. 1 . Breast implant-associated anaplastic large cell lymphoma. A, CT imaging showed seroma surrounding deflated left breast implant. 
B, Hematoxylin and eosin–stained section of capsulectomy specimen with BIA-ALCL underlying the surface.
Fig. 2. Invasive ductal carcinoma. A, Left diagnostic mammogram showing spiculated mass (circled) 
on craniocaudal view. B, Hematoxylin and eosin–stained section of partial mastectomy specimen with 
grade 2 IDC.
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detected. No pathogenic or likely pathogenic germline al-
terations were seen in the normal tissue. No somatic vari-
ants were shared between the two malignancies (see table, 
Supplemental Digital Content 3, which displays all somatic 
variants detected in the BIA-ALCL, http://links.lww.com/
PRSGO/B35; and see table, Supplemental Digital Content 
4, which displays all somatic variants detected in the IDC, 
http://links.lww.com/PRSGO/B36).
The mean target sequencing coverage was 68 and 711 
unique reads per target interval for the BIA-ALCL and 
IDC, respectively.
EVALUATION AND MANAGEMENT  
OF BIA-ALCL
ALCL is a rare entity, characterized by CD30 positivity 
and classified by clinical presentation (systemic versus cu-
taneous) and the presence or absence of rearrangements 
of ALK.4 In 1997, the first case of ALCL occurring in the 
periprosthetic tissue surrounding a breast implant was re-
ported.5 Since then, numerous reports of a new clinico-
pathologic entity, BIA-ALCL, have been published, with 
approximately 500 cases reported worldwide.6,7 Although 
the etiology is unclear, BIA-ALCL is associated with tex-
tured implants and the presence of bacterial biofilm.8 
The typical presenting symptom is a late periprosthetic 
seroma, but the detection of a mass, capsular contracture, 
axillary lymphadenopathy, B-type symptoms, and skin le-
sions have also been noted.6 Although the systemic form 
of ALK-negative ALCL typically has a poor prognosis, BIA-
ALCL confined to the periprosthetic fluid appears to have 
favorable outcomes in most cases.7
Recent work has begun to characterize the molecular 
landscape of BIA-ALCL. The largest series to date showed 
that all cases of BIA-ALCL were negative for the altera-
tions reported in other ALCL subtypes, namely, rearrange-
ments in ALK, DUSP22, and TP63.9 Instead, alterations in 
JAK-STAT genes are relatively common (27% of cases), 
and the STAT3 missense variant we identified (p.S614R) 
has been previously reported in 3 other cases of BIA-ALCL 
and in the TLBR1 BIA-ALCL cell line.9–12 Located in the 
SH2 domain, this gain-of-function mutation results in en-
hanced transcriptional activity of STAT3. Also reported in 
systemic ALK-negative and cutaneous ALCL, STAT3 muta-
tions are increased in malignancies associated with persis-
tent immune stimulation.7,11,13 Although the pathogenesis 
of BIA-ALCL is unknown, the presence of inflammatory 
cytokines such as IL-6 and IL-13 suggests a component 
of allergy and aberrant immune response in its develop-
ment.7,13
Profiling of the synchronous IDC showed no common 
genetic aberrations with the BIA-ALCL, suggesting dif-
ferent mechanisms of pathogenesis. The IDC harbored 
a PIK3CA alteration, which is seen in approximately 30% 
of breast cancers, and more commonly in estrogen recep-
tor-positive tumors.14 Aberrant PIK3CA activation drives 
cellular proliferation and survival, and gain-of-function 
mutations are able to transform normal breast epithelial 
cells to carcinoma. Currently, trials of PI3K inhibitors for 
advanced/metastatic breast cancer are ongoing.15 Interest-
ingly, PIK3CA-mutant breast cancer mouse models show 
upregulated STAT3 signaling compared to other mouse 
models of breast carcinogenesis, and inhibition of STAT3 
sensitizes tumor cells to PI3K inhibitors.16
Awareness of the initial evaluation and management of 
BIA-ALCL, and the possibility of discovering concomitant 
malignancies are critical for plastic surgeons. Although 
early treatment of BIA-ALCL was variable, efforts by the 
Food and Drug Administration (FDA), implant manufac-
turers, national professional organizations, and physician 
scientists across many specialties have led to multidisci-
plinary consensus guidelines to aid in diagnosis, treat-
ment, and tracking of this disease. In 2017, the National 
Comprehensive Cancer Network gathered medical, surgi-
cal, and radiation oncologists and plastic surgeons to cre-
ate guidelines to better standardize the management of 
BIA-ALCL.
Fig. 3. STAT3 alteration in breast implant-associated anaplastic large 
cell lymphoma. A, Lollipop plot and (B) Integrative Genomics Viewer 
depiction of STAT3 p.S614R variant in BIA-ALCL. Lollipop plot was 
modified from cBioPortal.3 C, The BIA-ALCL was positive for phos-
pho-STAT3 (Tyr705) by immunohistochemistry.
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Preoperative Consultation
The initial consultation with a patient considering 
prosthetic breast reconstruction or augmentation should 
include a discussion about the risk of BIA-ALCL.17 The risk 
is thought to be equal between reconstructive and cosmet-
ic patients and has variable incidence based on geograph-
ic location.18,19 Currently, the lifetime risk for developing 
BIA-ALCL in women with textured implants is between 1 
in 4,000 and 30,000 in the United States, but may be as 
high as 1 in 1,000 in Australia.20 This risk is much lower 
than the background risk of breast cancer in women, esti-
mated at 12.4%, or the risk of recurrence in patients who 
have had a mastectomy.21
Intraoperative Decision Making
In both patients undergoing augmentation mammo-
plasty and patients undergoing prosthetic breast recon-
struction, the risk of subsequently developing BIA-ALCL 
appears to be similar.1 Currently, no data on implant loca-
tion (submuscular or prepectoral) exist to dictate whether 
the plane of implant placement affects risk.22 Of the over 
500 cases reported to date, only patients who have had 
a textured implant or expander have been confirmed to 
develop BIA-ALCL.23 Therefore, consideration should 
be paid to whether the benefits of implant texturing are 
worth the increased risk of developing this rare disease. 
As inflammation possibly from bacterial contamination at 
the time of surgery is thought to play a role in the devel-
opment of BIA-ALCL, a 14-point intraoperative plan has 
been suggested which outlines various steps throughout 
a case that may help reduce the risk of contamination.24
Standard Postoperative Care
After routine postoperative care, there are no specific 
guidelines for routine monitoring to detect BIA-ALCL. 
Existing FDA recommendations suggest that patients 
with silicone implants undergo screening for silent rup-
ture with magnetic resonance imaging of the breast at 3 
years after placement, followed by every 2 years.25 Mam-
mography should be obtained for breast cancer screening 
or surveillance based on prior oncologic history.26 Patients 
should receive education about the natural history of 
BIA-ALCL, typically presenting as a late-onset fluid collec-
tion, asymmetric swelling, mass, or skin changes any time 
after 1 year from implant placement.27,28 Although more 
common causes such as trauma or infection can result in 
these changes, and the absolute risk of ALCL in patients 
with these findings is low, patients should be instructed 
to reach out to their plastic surgeon for comprehensive 
evaluation.
Patients presenting for evaluation of suspected BIA-
ALCL should have a thorough surgical and oncologic his-
Fig. 4. PIK3CA alteration in invasive ductal carcinoma. A, Lollipop plot and (B) Integrative Genomics 
Viewer depiction of PIK3CA p.G106_R108del variant in IDC. Lollipop plot was modified from cBioPortal.3
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tory obtained with the dates and specifics of procedures 
and treatments including what type of implant was placed. 
Clinical history of the changes that prompted evaluation 
should also be addressed. Physical exam should evaluate 
the chest for implant asymmetry, malposition, presence of 
a clinically palpable effusion or mass, skin changes, and 
regional adenopathy. Any abnormality should prompt 
subsequent imaging.29
Imaging Studies
The initial diagnostic test of choice is breast ultra-
sound to evaluate for periprosthetic fluid collection, mass, 
or regional adenopathy.26,28–30 The sensitivity of detection 
of a fluid collection in a patient with BIA-ALCL is 84% 
based on one retrospective study, and lower for detection 
of a mass at 46%. The specificity for effusion and mass 
detection were 75% and 100%, respectively.31 If an effu-
sion is found, fluid should be aspirated and sent for evalu-
ation. At least 20 ml of fluid should be sampled if possible, 
but volumes of 50–100 ml are ideal to decrease the risk of 
false negative or indeterminate findings.26 Fluid should be 
sent for culture and Gram stain, cell block cytology, im-
munohistochemistry, and flow cytometry.28–30 Alerting the 
pathologist that BIA-ALCL is a diagnostic consideration is 
important to ensure appropriate tests (including compre-
hensive flow cytometric markers) are done.
If ultrasound evaluation is inconclusive, breast mag-
netic resonance imaging can be considered because it 
is the next most sensitive imaging test for effusion.31 If 
a mass is found, biopsy should be performed. CT and 
mammography lack sufficient sensitivity and specific-
ity to recommend their use in the workup of BIA-ALCL. 
However, PET should be considered in selected cases to 
provide information about the extent of local disease and 
the presence of metastatic disease once diagnosis of BIA-
ALCL is made.26,29–31 Current guidelines for the workup 
of BIA-ALCL do not include the use of mammography 
in the preoperative evaluation.30 However, the diagnosis 
of ipsilateral IDC 6 months later in this patient suggests 
that thorough diagnostic breast imaging including mam-
mography should be obtained prior to breast surgery. 
Although impossible to know whether mammography at 
the time of BIA-ALCL diagnosis would have identified the 
IDC, PET/CT is not a reliable replacement for thorough 
diagnostic workup of the breast, as the sensitivity for detec-
tion of primary breast tumors is reported to be only 68% 
for tumors less than 2 cm in size.32
Consultations
Patients with negative findings for lymphoma on initial 
workup may be appropriately managed by a plastic sur-
geon for management of seroma or infection. However, 
an indeterminate diagnosis on initial pathology warrants 
additional workup. This may include having the slides 
sent to an outside pathologist or referral to a tertiary care 
center, either of whom with experience in treatment of 
BIA-ALCL.30 A diagnosis of lymphoma should result in re-
ferral to a center with a multidisciplinary team of medical, 
surgical, and radiation oncologists, plastic surgeons, and 
hematopathologists.1,6
Surgery
Removal of the implant and total capsulectomy re-
mains the mainstay of therapy for BIA-ALCL and is cu-
rative in a majority of cases.1,31 Consideration should be 
given to having a surgical oncologist present at the time 
of surgery, especially with extensive disease or need for 
lymph node surgery. Sentinel lymph node biopsy is not 
routinely recommended given the variable drainage pat-
terns of the large breast implant capsule, but the removal 
of suspicious lymph nodes at the time of implant remov-
al is recommended.1,26,27,30 Removal of the contralateral 
breast implant at the time of surgery is not mandated by 
guidelines, but reports of occult contralateral BIA-ALCL 
in patients undergoing implant removal with preopera-
tively diagnosed lymphoma should be discussed with pa-
tients.33 There are sparse studies evaluating the optimal 
timing of implant replacement following removal for BIA-
ALCL. Early data suggest immediate replacement is safe 
and has some advantages over delayed replacement, but 
surgeons should choose smooth implants and treat every 
patient on a case-by-case basis.33
Adjuvant Therapy
For patients with BIA-ALCL confined to the capsule 
or implant and who complete surgical resection with no 
residual disease, adjuvant therapy is not currently recom-
mended. For patients with evidence of lymphoma extend-
ing beyond the implant capsule or residual disease in the 
breast due to inability to completely resect the tumor, 
adjuvant therapy is indicated.1,29,33 Adjuvant therapy deci-
sions should be made in a multidisciplinary setting on a 
case-by-case basis, but in general radiation therapy (24–36 
Gy) is advocated for residual local disease in patients with-
out a history of prior chest wall radiation, and chemother-
apy is advocated for patients with positive lymph nodes 
or evidence of spread to distant sites. The most common 
chemotherapeutic agents or regimens include brentux-
imab vedotin, a monoclonal antibody targeting CD30 with 
individual case reports demonstrating efficacy in BIA-
ALCL, or chemotherapy combinations recommended 
for peripheral T-cell lymphomas such as cyclophospha-
mide, doxorubicin, vincristine, and prednisone or varia-
tions thereof.26,34–36
Follow-up
After primary management, National Comprehensive 
Cancer Network guidelines recommend surveillance for 
recurrence of BIA-ALCL for a minimum of 2 years with 
physical examination and, if indicated, CT chest/abdo-
men/pelvis or whole body PET/CT every 6 months, af-
ter which patients should resume routine breast cancer 
screening.30 The development of recurrent clinical find-
ings in the breast at any point should prompt referral back 
to their plastic surgeon, and warrants repeat diagnostic 
imaging.
Reporting
All cases of BIA-ALCL should be reported to the FDA 
through their MedWatch adverse events reporting pro-
gram. In addition, the Plastic Surgery Foundation has set 
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up a registry called Patient Registry and Outcomes For 
breast Implants and ALCL etiology and Epidemiology 
(PROFILE) that helps track and better understand the 
causes and treatments of BIA-ALCL.19
CONCLUSIONS
To the best of our knowledge, this is the first report 
of a patient with synchronous BIA-ALCL and IDC in the 
same breast. This case illustrates the importance of evalu-
ating for additional malignancies in the breast when a di-
agnosis of BIA-ALCL is made; diagnostic mammogram at 
the time of workup of BIA-ALCL may be a useful adjunct 
to ultrasound and PET/CT to identify additional breast 
malignancies prior to surgery. Future studies may identify 
susceptibility factors and further elucidate the potential 
relationship between BIA-ALCL and IDC.
Gregory R. Bean, MD, PhD
Department of Pathology
Stanford University School of Medicine
300 Pasteur Dr. Room H2121
Stanford, CA 94305
E-mail: beang@stanford.edu
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